Timo Karvinen appointed to Medaffcon’s Market Access team
Timo Karvinen joined Medaffcon’s Market Access team as an expert in the beginning of May. In addition to his extensive expertise, he also brings a whole new service concept to Medaffcon.
All articles
-
-
Smoking clearly increases the risk of postoperative complications
Register study undisputedly confirms that a smoker’s risk for any postoperative complications is significantly higher than non-smokers’.
-
Finnish health data mirror the entire patient pathway
Finnish hospitals’ data lakes offer an opportunity to access tremendously rich real-world data on treatments and outcomes that enable research on topics ranging from medical questions to health economics.
-
New study: Treatment costs of heart failure increase tenfold in exacerbation
The result of a recent original study surprised the researchers: the costs of treating heart failure tenfold in exacerbation. The results were published in Duodecim on 23 March 2023.
-
Medaffcon’s Market Access team provides a vantage point to the entire industry
The Market Access team works actively with different actors, while helping customers in processes related to market access and market presence and in strategic planning.
-
The burden of Chronic Rhinosinusitis with Nasal Polyps and its relation to Asthma in Finland
In this nationwide register study, we described the incidence, prevalence, and treatment burden of chronic rhinosinusitis with nasal polyps (CRSwNP), and its disease association with asthma from 2012 to 2018 in Finland.
-
Health from Data takes a look at the past and the future
Health from Data blog was founded in 2021. It’s the third year and this is...
-
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016
Our recent RWE study detailed the comorbidity burden of Finnish multiple myeloma (MM) patients diagnosed between 2005 and 2016.
-
Text mining helped analyse a million entries on smoking
How to review and analyse a million sentences? Text mining decreased the work of clinical experts and accelerated the research process.
-
Heini Honkanen appointed as Medaffcon’s Market Access Lead
Heini Honkanen has been appointed as Medaffcon’s Market Access Lead. The new Market Access Team was created when the previous Price and Reimbursement and HE & Access Teams were merged.
-
RWE provides information for many needs
Real-world evidence (RWE) studies are usually started with a specific use for results in mind....
-
Unstructured healthcare data contributes to solving new issues
Finland has unique data for pharmaceutical purposes and unstructured healthcare data can also be already effectively utilised.
-
Greetings from ISPOR: the use of Real World Evidence is becoming more common
Medaffconin Tanja Nieminen ja Heini Honkanen osallistuivat terveystaloustieteen tutkimukseen ja terveydenhuollon menetelmien arviointiin keskittyvään ISPOR-kongressiin marraskuussa.
-
“We always provide the customer with a solution to their problem”
CEO Jarmo Hahl explains what Medaffcon’s service entity consists of and what makes Medaffcon an excellent partner for their customers.
-
Virtual control groups in pharmaceutical development – What are they and can they be trusted?
Single-arm research designs are challenging for a pharmaceutical reimbursement and marketing authorisation process.
-
Findata reformed the processing of data permit applications – customers benefit in a diversity of manners
Finnish Social and Health Data Permit Authority Findata has significantly reformed and accelerated the processing...
-
Need for medicine-related data increases, the system responds to the change slowly
It would be useful to have RWE support the decision-making related to managed introduction and...
-
RWE complements the overall picture of the authorities
In health economic studies, real world evidence (RWE) can produce additional knowledge, especially on the...
-
A clinician’s perspective: The reimbursement of a medicine impacts the selected treatment
The basic reimbursement granted for medicinal substance teduglutide was a significant step forward for children...
-
Gaucher study provides new aspects in rare disease screening and the utilization of data and specimens of the Finnish biobanks
The study assessed the prevalence of Gaucher disease in Finland and developed methods to screen...
-
World of methodologies | Virtual control arms provide more data for decision making
Recently, there has been a lot of discussion on virtual control arms. In this blog...
-
Real world evidence supports the market access of medicines – teduglutide as an example
We already have clinical medicine trials. Why on earth do we also need real world...
-
Cardiovascular outcome according to renal status in Finnish patients with type 2 diabetes
Chronic kidney disease has been suggested as the main contributor to the increased cardiovascular morbidity...
-
Medicines data repository would decrease overlapping work
Planning of a medicines data repository compiling different data sets is well underway, which is...
-
Synthetic data and a common data register – the future of real-world evidence is fast approaching
Utilisation of real-world evidence (RWE) progresses at speed and development steps are fast. Utilising real-world...
-
Studies that utilise real-world evidence consolidate relations with clinicians
Studies relying on real-world evidence help clinicians to create a better overall picture of the...
-
Pioneers already utilise real-world evidence actively
The results of studies based on real-world data (RWD) have convinced also people that were...
-
Enjoy your summer vacation and come back fast – Interesting RWE to be published this year
Last summer the readers of my blog guessed that the number of real-world evidence (RWE)...
-
Safety from Data | How patient register data can add to the safety and effectiveness of pharmacotherapy
The safety and efficacy of pharmacotherapy can be measured in multiple ways during the different...
-
Real-world evidence completes clinical trials – the significance of data may increase in the future
RWE or real-world evidence provides authorities assessing pharmacotherapies with data on the prevalence of a...
-
Registry data to support clinical trials
Randomized clinical trials (RCT) have traditionally been held up as the gold standard for studying...
-
Medical authority values the consistency of health economic evaluations
Health economic evaluations bring additional information to the authorities’ decision-making concerning medicinal products. How does...
-
Uncertainty is always present when assessing the introduction of a new medicine
From the perspective of decision-making, it is important that a health economic evaluation conducted on...
-
Patients with atherosclerotic cardiovascular disease are at high risk of death after the first cardiovascular event, shows a Finnish real-world evidence study
Cardiovascular diseases are the leading cause of disability and premature death worldwide. Real-world evidence (RWE)...
-
National price negotiation of hospital-only medicinal products is not an auction
HUS Pharmacy Director Kerstin Carlsson reveals the process of national price negotiation of hospital-only medicinal...
-
Utilisation of Finnish hospital data lake data to analyse diffuse large B-cell lymphoma (DLBCL) in a real-world setting: Recording practices at routine care should be developed
Real-world data on diffuse large B-cell lymphoma (DLBCL) has remained incomplete. In Finland, electronic health...
-
World of methodologies | Unstructured data and Machine learning in Real-World Evidence studies
We start this year in the world of methodologies with a hot topic of utilizing...
-
Medaffcon welcomes Omicron and Value Coaching into the cooperation network
Medaffcon expands its network of companies to Omicron ApS and Value Coaching Oy to extend...
-
A look back at the real-world evidence year of 2021
With the ninth Health from Data blog post and the end of the year closing...
-
What happens to a patient in real life is visible through Real-World Evidence
A real-world evidence (RWE) study makes visible what happens to a group of patients in...
-
World of methodologies | Supervised machine learning and classifiers
We took the first glimpse into the world of methodologies earlier this year when Medaffcon’s...
-
What makes Finland’s real world data special? Four ingredients for success.
The Finnish health and social care registries are unique from an international perspective. Thus, real-world...
-
Hip and knee osteoarthritis more than doubles the number of sick leave days and occupational healthcare contacts for working age individuals
Research has shown that osteoarthritis causes disability, especially among older adults. Our latest real-world evidence...
-
History of Real-World Evidence
Real-world evidence (RWE) is relatively young. However, RWE-research has its roots in the traditional registry-based...
-
LINK Medical and Medaffcon join forces in Real World Evidence (RWE) and Market Access to offer customers full support across the Nordics
OSLO, Norway/ ESPOO, Finland May 24, 2021 LINK Medical, the Northern European clinical research organization...